Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | CA9 | Q16790 | 7/20 | 0.47 |
| ▸ | ACHE | P22303 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755488 | 0.94 | TDP1 (0.57) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL14523047 | 0.92 | TDP1 (0.56) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL13752387 | 0.91 | TDP1 (0.53) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18041278 | 0.89 | MAOA (0.54) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL17169750 | 0.89 | TDP1 (0.51) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL25755598 | 0.89 | TDP1 (0.51) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL20193876 | 0.89 | TDP1 (0.51) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL17538394 | 0.87 | TDP1 (0.57) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22783858 | 0.87 | MAOA (0.48) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL29216441 | 0.87 | MAOA (0.55) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | TDP1 4479/4885MAOA 816/4885MAOB 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.